These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29069415)

  • 1. Serotype-Specific Correlates of Protection for Pneumococcal Carriage: An Analysis of Immunity in 19 Countries.
    Voysey M; Fanshawe TR; Kelly DF; O'Brien KL; Kandasamy R; Shrestha S; Thorson S; Hinds J; Pollard AJ
    Clin Infect Dis; 2018 Mar; 66(6):913-920. PubMed ID: 29069415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage.
    Ojal J; Hammitt LL; Gaitho J; Scott JAG; Goldblatt D
    Vaccine; 2017 Aug; 35(35 Pt B):4652-4657. PubMed ID: 28739116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine.
    Akinsola AK; Ota MO; Enwere GC; Okoko BJ; Zaman SM; Saaka M; Nsekpong ED; Odutola AA; Greenwood BM; Cutts FT; Adegbola RA
    PLoS One; 2012; 7(2):e31050. PubMed ID: 22363544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.
    Dagan R; Givon-Lavi N; Porat N; Greenberg D
    Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers.
    Gurung M; Bijukchhe SM; Hariri P; Voysey M; Kandasamy R; Thorson S; Maskey P; Pandit R; Shrestha B; Gautam MC; Maharjan M; Lama L; Acharya B; Basi R; K C M; O'Reilly P; Shrestha S; Ansari I; Shah GP; Kelly S; O'Brien KL; Goldblatt D; Kelly DF; Murdoch DR; Pollard AJ; Shrestha S
    Pediatr Infect Dis J; 2021 Oct; 40(10):937-943. PubMed ID: 34292271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
    Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
    Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial.
    Kandasamy R; Gurung M; Thorson S; Yu LM; Galal U; Voysey M; Kelly S; Wahl B; Berbers G; Finnegan K; Ansari I; Paudel K; Murdoch DR; O'Brien KL; Kelly DF; Goldblatt D; Shrestha S; Pollard AJ
    Lancet Infect Dis; 2019 Feb; 19(2):156-164. PubMed ID: 30635252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy and Duration of Protection of Pneumococcal Conjugate Vaccines Against Nasopharyngeal Carriage: A Meta-regression Model.
    Le Polain De Waroux O; Flasche S; Prieto-Merino D; Goldblatt D; Edmunds WJ
    Pediatr Infect Dis J; 2015 Aug; 34(8):858-64. PubMed ID: 26075814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration.
    Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
    Vaccine; 2016 Aug; 34(36):4313-20. PubMed ID: 27422342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal Carriage in Children under Five Years in Uganda-Will Present Pneumococcal Conjugate Vaccines Be Appropriate?
    Lindstrand A; Kalyango J; Alfvén T; Darenberg J; Kadobera D; Bwanga F; Peterson S; Henriques-Normark B; Källander K
    PLoS One; 2016; 11(11):e0166018. PubMed ID: 27829063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.
    Feng S; McLellan J; Pidduck N; Roberts N; Higgins JP; Choi Y; Izu A; Jit M; Madhi SA; Mulholland K; Pollard AJ; Procter S; Temple B; Voysey M
    Health Technol Assess; 2024 Jul; 28(34):1-109. PubMed ID: 39046101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasopharyngeal s. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme.
    Wouters I; Van Heirstraeten L; Desmet S; Blaizot S; Verhaegen J; Goossens H; Van Damme P; Malhotra-Kumar S; Theeten H;
    Vaccine; 2018 Jan; 36(1):15-22. PubMed ID: 29180027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rise and fall of pneumococcal serotypes carried in the PCV era.
    Devine VT; Cleary DW; Jefferies JM; Anderson R; Morris DE; Tuck AC; Gladstone RA; O'Doherty G; Kuruparan P; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2017 Mar; 35(9):1293-1298. PubMed ID: 28161425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation.
    Dagan R
    Expert Rev Vaccines; 2019 Jun; 18(6):641-661. PubMed ID: 31230486
    [No Abstract]   [Full Text] [Related]  

  • 15. A toddler PCV booster dose following 3 infancy priming doses increases circulating serotype-specific IGG levels but does not increase protection against carriage.
    Dagan R; Ben-Shimol S; Simell B; Greenberg D; Porat N; Käyhty H; Givon-Lavi N
    Vaccine; 2018 May; 36(20):2774-2782. PubMed ID: 29655626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings.
    Cheung YB; Zaman SM; Nsekpong ED; Van Beneden CA; Adegbola RA; Greenwood B; Cutts FT
    Pediatr Infect Dis J; 2009 Nov; 28(11):990-5. PubMed ID: 19536041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.
    Madhi SA; Violari A; Klugman KP; Lin G; McIntyre JA; von Gottberg A; Jean-Philippe P; Cotton MF; Adrian P;
    Vaccine; 2011 Sep; 29(40):6994-7001. PubMed ID: 21787822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data.
    Lipsitch M; Li LM; Patterson S; Trammel J; Juergens C; Gruber WC; Scott DA; Dagan R
    Vaccine; 2018 Jan; 36(4):473-478. PubMed ID: 29248266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among children in India prior to the introduction of pneumococcal conjugate vaccines: a cross-sectional study.
    Sutcliffe CG; Shet A; Varghese R; Veeraraghavan B; Manoharan A; Wahl B; Chandy S; Sternal J; Khan R; Singh RK; Santosham M; Arora NK
    BMC Infect Dis; 2019 Jul; 19(1):605. PubMed ID: 31291902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics and Determinants of Pneumococcal Antibodies Specific against 13 Vaccine Serotypes in the Pre-Vaccination Era.
    Prins-van Ginkel AC; Berbers GA; Grundeken LH; Tcherniaeva I; Wittenberns JI; Elberse K; Mollema L; de Melker HE; Knol MJ
    PLoS One; 2016; 11(1):e0147437. PubMed ID: 26796783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.